Jochmans I, Brat A, Davies L, et al. - Researchers undertook this randomised, double-blind, paired, phase 3 trial to determine if the outcome of kidneys donated following circulatory death could be improved by supplemental oxygen during hypothermic machine perfusion (HMP). They considered kidney pairs from donors aged 50 years or older, donated post-circulatory death, as eligible if both kidneys were transplanted into two different recipients. They randomly assigned one kidney from each donor to oxygenated hypothermic machine perfusion (HMPO₂), the other to HMP without oxygenation. Findings demonstrated not only the safety of HMPO₂ of kidneys donated after circulatory death but also its ability to cause reduction in post-transplant complications (grade IIIb or more). Between the HMPO₂ and HMP groups, there was no significant 12-month disparity in estimated glomerular filtration rate when both kidneys from the same donor were still functioning 1-year after transplant, however, HMPO₂ was suggested to have potential beneficial impacts based on the analysis of secondary outcomes.